July 23, 2016 5:18 PM ET


Company Overview of Relypsa, Inc.

Company Overview

Relypsa, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of polymeric medicines for patients with conditions that are overlooked and undertreated and can be addressed in the gastrointestinal tract primarily in the United States. The company offers Veltassa (patiromer), a non-absorbed potassium binding polymer for the treatment of hyperkalemia. It has license agreement with Vifor Fresenius Medical Care Renal Pharma Ltd. for developing and commercializing Veltassa outside the United States and Japan. The company was founded in 2007 and is headquartered in Redwood City, California.

100 Cardinal Way

Redwood City, CA 94063

United States

Founded in 2007

429 Employees



Key Executives for Relypsa, Inc.

Chief Executive Officer, President and Director
Age: 51
Total Annual Compensation: $546.3K
Chief Financial Officer, Principal Accounting Officer and Senior Vice President
Age: 44
Total Annual Compensation: $353.8K
Chief Commercial Officer and Senior Vice President
Age: 47
Total Annual Compensation: $465.0K
Chief Medical Officer and Senior Vice President
Age: 45
Total Annual Compensation: $415.0K
Chief Scientific Officer and Senior Vice President
Age: 51
Total Annual Compensation: $355.4K
Compensation as of Fiscal Year 2015.

Relypsa, Inc. Key Developments

Galenica Ltd., Relypsa, Inc. - M&A Call

To discuss the acquisition of Relypsa by Galenica

Relypsa Expects To Be Delisted From The NASDAQ Upon Acquisition Of Galenica Group

Galenica Group and Relypsa, Inc. announced that the companies have entered into a definitive agreement under which Galenica will acquire Relypsa. Under the terms of the merger agreement, Galenica will pay $32 per share in cash, or a total of approximately $1.53 billion. Through this acquisition, Vifor Pharma will gain a fully-integrated commercial organization in the United States and significantly strengthen its presence in the U.S. cardio-renal market, a key area of focus. Subject to customary conditions, including the tender of the majority of the outstanding Relypsa shares and the expiration or earlier termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, the transaction is expected to close during the third quarter of 2016. Relypsa is expected to be delisted from the NASDAQ and integrated into Vifor Pharma thereafter.

Relypsa, Inc. Presents at Cantor Fitzgerald 2nd Annual Healthcare Conference, Jul-12-2016 02:30 PM

Relypsa, Inc. Presents at Cantor Fitzgerald 2nd Annual Healthcare Conference, Jul-12-2016 02:30 PM. Venue: Le Parker Meridien, New York, New York, United States. Speakers: John A. Orwin, Chief Executive Officer, President and Director.

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

July 21, 2016
Private Placement
April 27, 2016

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Relypsa, Inc., please visit www.relypsa.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.